title: Lipocalin-2, glucose metabolism and chronic low-grade systemic inflammation in Chinese people.
abstract: BACKGROUND
  Lipocalin-2 is a novel adipokine with connection to insulin resistance. In this study, we aimed to investigate the association of serum lipocalin-2 with glucose metabolism and other metabolic phenotype in a large-scale Chinese population.
  
  
  METHODS
  We evaluated serum lipocalin-2 in a cross-sectional sample of 2519 Chinese aged from 50 to 82 year in a Shanghai downtown district by ELISA. Glucose, insulin, lipid profile, inflammatory markers, and adipokines were also measured.
  
  
  RESULTS
  Serum lipocalin-2 was significantly higher in subjects with isolated impaired fasting glucose, isolated impaired glucose tolerance, combined impaired fasting glucose/impaired glucose tolerance and newly-diagnosed type 2 diabetes than in those with normal glucose regulation. Lipocalin-2 elevation was clearly associated with a higher risk for impaired glucose regulation (OR 1.30 for each 10 ng/ml increase in serum lipocalin-2, 95% CI 1.23-1.62, p = 0.009) after adjustment of age, gender, smoking, alcohol drinking, family history of diabetes, serum CRP, serum adiponectin, serum CXCL5, HOMA-IR, BMI, and waist/hip ratio. The OR for participants with impaired glucose regulation and type 2 diabetes was 1.31 (95% CI 1.21-1.69, p < 0.001).
  
  
  CONCLUSIONS
  Our findings suggest that elevated serum lipocalin-2 is closely and independently associated with impaired glucose regulation and type 2 diabetes.
authors.affiliation: Institute of Endocrinology and Diabetology, Huashan hospital, Shanghai Medical College, Fudan University, Shanghai, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Huang
authors.forename: Zhen
authors.initials: Z
authors.lastname: Yang
authors.forename: Zi
authors.initials: Z
authors.lastname: Ye
authors.forename: Qin
authors.initials: Q
authors.lastname: Li
authors.forename: Jie
authors.initials: J
authors.lastname: Wen
authors.forename: Xiaoming
authors.initials: X
authors.lastname: Tao
authors.forename: Lili
authors.initials: L
authors.lastname: Chen
authors.forename: Min
authors.initials: M
authors.lastname: He
authors.forename: Xuanchun
authors.initials: X
authors.lastname: Wang
authors.forename: Bin
authors.initials: B
authors.lastname: Lu
authors.forename: Zhaoyun
authors.initials: Z
authors.lastname: Zhang
authors.forename: Weiwei
authors.initials: W
authors.lastname: Zhang
authors.forename: Shen
authors.initials: S
authors.lastname: Qu
authors.forename: Renming
authors.initials: R
authors.lastname: Hu
mesh_terms: D000209:Acute-Phase Proteins; D054392:Adipokines / Q000097:blood; D000368:Aged; D000369:Aged, 80 and over; D044466:Asian People; D001786:Blood Glucose / Q000378:metabolism*; D002681:China; D002908:Chronic Disease; D003430:Cross-Sectional Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000175:diagnosis / Q000208:ethnology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D018149:Glucose Intolerance / Q000097:blood* / Q000175:diagnosis / Q000208:ethnology; D006801:Humans; D007249:Inflammation / Q000097:blood* / Q000208:ethnology; D018836:Inflammation Mediators / Q000378:metabolism; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D008055:Lipids / Q000097:blood; D000071068:Lipocalin-2; D054834:Lipocalins / Q000097:blood*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D016017:Odds Ratio; D010641:Phenotype; D011518:Proto-Oncogene Proteins / Q000097:blood*; D018570:Risk Assessment; D012307:Risk Factors; D015854:Up-Regulation
chemical_list: D000209:Acute-Phase Proteins; D054392:Adipokines; D001786:Blood Glucose; D018836:Inflammation Mediators; D007328:Insulin; C489506:LCN2 protein, human; D008055:Lipids; D000071068:Lipocalin-2; D054834:Lipocalins; D011518:Proto-Oncogene Proteins